Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3468 - A Single Centre Retrospective Review of Testosterone Deficiency in Germ Cell Cancer Patients

Date

10 Sep 2017

Session

Poster display session

Presenters

Lara Gibbs

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

L.S. Gibbs, G.L. Gullick, E. Allison, S. Brand, A. Addeo, A. Kuchel, J. Braybrooke

Author affiliations

  • Bristol Cancer Institute, University Hospitals Bristol NHS Trust Bristol Haematology and Oncology Centre, BS2 8ED - Bristol/GB
More

Resources

Abstract 3468

Background

Testosterone deficiency syndrome (TDS) is frequently described in men treated for germ cell cancer with rates quoted between 11 and 38% (Huddart et al 2005). Observational studies show that TDS reduces quality of life and carries cardiovascular, metabolic and bone health risks. At our institute we observed that men with symptoms of TDS and ‘low normal’ testosterone (T) (8.6 – 12 nmol/L) were not reliably recognised.

Methods

We collected retrospective data from all germ cell cancer referrals to the Bristol Cancer Institute from 2011 – 2016. We documented age, treatment, at least one random T level within a year of diagnosis (grouped into < 8, 8 – 12 and > 12 nmol/L), details of symptoms and treatment of TDS.

Results

Data was collected on 462 patients (36 excluded with non germ cell diagnoses and 26 excluded due to T never being measured). Median age was 36 years (range 17 – 89) with 85% of patients aged under 50. 58% of men had seminoma, 32% non-seminoma and 10% combined germ cell cancer. 41% of all patients had a T level < 12 nmol/L at first measurement (32% of 20 – 29 year olds, 42% of 30 – 49 and 58% of 50 – 59 year olds) and 16% had T 

Conclusions

In this retrospective series 41% of patients had at least one total T value

Clinical trial identification

Legal entity responsible for the study

Jeremy Braybrooke

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.